Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 20

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
6   729   2027   405   Total lease payments   1,202   Less: imputed interest   (122)  Present value of future lease payments   1,080   Less: operating lease, current liabilities   (457)  Long-term operating lease liabilities  $623         
 Weighted-average remaining lease term   1.7 years           Weighted-average discount rate   12.0% 

During the three and nine months ended September
30, 2025 the Company recognized $134,000 and $229,000, respectively, of lease expense.

During the three and nine months ended September
30, 2024, the Company recognized $40,000 and $120,000, respectively, of lease expense.

During April 2025, the Company’s wholly-owned
subsidiary, INmune Bio International. Ltd., entered into a 2-year collaboration agreement with a vendor whereby it makes fixed payments
to the vendor in exchange for services pursuant to manufacturing CORDStrom in the United Kingdom. A summary of the commitments payable
for these services pursuant to the agreement is as follows as of September 30, 2025:

    (in thousands, except years) 

    2026 
    $1,449 
  
    2027 
     1,177 
  
    Total 
    $2,626 

13

NOTE 7 – RELATED PARTY TRANSACTIONS

UCL

During
the nine months ended September 30, 2025 and 2024, the Company made payments to UCL of $132,000 and $252,000, respectively, for medical
research performed on behalf of the Company. UCL is a wholly owned subsidiary of the University of London. The Company’s Chief
Scientific and Manufacturing Officer is a professor at the University of London.

AmplifyBio

At September
30, 2025 and December 31, 2024, the Company recorded a payable to AmplifyBio of $26,000 and $0, respectively, for medical research performed
on behalf of the Company. During the nine months ended September 30, 2025 and 2024, the Company paid AmplifyBio $41,000 and $324,000,
respectively. During 2025, AmplifyBio ceased operations. Amplify